newsfilter
← Latest News
GlobeNewswire·

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying